Momentum state engineering and control in Bose-Einstein condensates

We demonstrate theoretically the use of genetic learning algorithms to coherently control the dynamics of a Bose-Einstein condensate. We consider specifically the situation of a condensate in an optical lattice formed by two counterpropagating laser beams. The frequency detuning between the lasers acts as a control parameter that can be used to precisely manipulate the condensate even in the presence of a significant mean-field energy. We illustrate this procedure in the coherent acceleration of a condensate and in the preparation of a superposition of prescribed relative phase.Comment: 9 pages incl. 6 PostScript figures (.eps), LaTeX using RevTeX, submitted to Phys. Rev. A, incl. small modifications, some references adde

Practice guidelines for diseases caused by Aspergillus

Aspergillosis comprises a variety of manifestations of infection. These guidelines are directed to 3 principal entities: invasive aspergillosis, involving several organ systems (particularly pulmonary disease); pulmonary aspergilloma; and allergic bronchopulmonary aspergillosis. The recommendations are distilled in this summary, but the reader is encouraged to review the more extensive discussions in subsequent sections, which show the strength of the recommendations and the quality of the evidence, and the original publications cited in detail. Invasive aspergillosis. Because it is highly lethal in the immunocompromised host, even in the face of therapy, work-up must be prompt and aggressive, and therapy may need to be initiated upon suspicion of the diagnosis, without definitive proof (BIII). Intravenous therapy should be used initially in rapidly progressing disease (BIII). The largest therapeutic experience is with amphotericin B deoxycholate, which should be given at maximum tolerated doses (e.g., 1-1.5 mg/kg/d) and should be continued, despite modest increases in serum creatinine levels (BIII). Lipid formulations of amphotericin are indicated for the patient who has impaired renal function or who develops nephrotoxicity while receiving deoxycholate amphotericin (AII). Oral itraconazole is an alternative for patients who can take oral medication, are likely to be adherent, can be demonstrated (by serum level monitoring) to absorb the drug, and lack the potential for interaction with other drugs (BII). Oral itraconazole is attractive for continuing therapy in the patient who responds to initial iv therapy (CIII). Therapy should be prolonged beyond resolution of disease and reversible underlying predispositions (BIII). Adjunctive therapy (particularly surgery and combination chemotherapy, also immunotherapy), may be useful in certain situations (CIII). Aspergilloma. The optimal treatment strategy for aspergilloma is unknown. Therapy is predominantly directed at preventing life-threatening hemoptysis. Surgical removal of aspergilloma is definitive treatment, but because of significant morbidity and mortality it should be reserved for high-risk patients such as those with episodes of life-threatening hemoptysis, and considered for patients with underlying sarcoidosis, immunocompromised patients, and those with increasing Aspergillus-specific IgG titers (CIII). Surgical candidates would need to have adequate pulmonary function to undergo the operation. Bronchial artery embolization rarely produces a permanent success, but may be useful as a temporizing procedure in patients with life-threatening hemoptysis. Endobronchial and intracavitary instillation of antifungals or oral itraconazole may be useful for this condition. Since the majority of aspergillomas do not cause life-threatening hemoptysis, the morbidity and cost of treatment must be weighed against the clinical benefit. Allergic bronchopulmonary aspergillosis (APBA). Although no well-designed studies have been carried out, the available data support the use of corticosteroids for acute exacerbations of ABPA (AII). Neither the optimal corticosteroid dose nor the duration of therapy has been standardized, but limited data suggest the starting dose should be 0.5 mg/kg/d of prednisone. The decision to taper corticosteroids should be made on an individual basis, depending on the clinical course (BIII). The available data suggest that clinical symptoms alone are inadequate to make such decisions, since significant lung damage may occur in asymptomatic patients. Increasing serum IgE levels, new or worsening infiltrate on chest radiograph, and worsening spirometry suggest that corticosteroids should be used (BII). Multiple asthmatic exacerbations in a patient with ABPA suggest that chronic corticosteroid therapy should be used (BIII). Itraconazole appears useful as a corticosteroid sparing agent (BII). Although the frequency of these diseases in on the rise, there is a paucity of randomized comparative trials involving these entities; therefore, the recommendations represent a compromise and consensus among students of these diseases (i.e., the authors). They have synthesized the recommendations from published and personal experience, including case series, open trilas, and any comparative trials, as indicated

Traumatic spinal cord injury in Victoria, 2007–2016

Objective: To investigate trends in the incidence and causes of traumatic spinal cord injury (TSCI) in Victoria over a 10-year period. Design, setting, participants: Retrospective cohort study: analysis of Victorian State Trauma Registry (VSTR) data for people who sustained TSCIs during 2007–2016. Main outcomes and measures: Temporal trends in population-based incidence rates of TSCI (injury to the spinal cord with an Abbreviated Injury Scale [AIS] score of 4 or more). Results: There were 706 cases of TSCI, most the result of transport events (269 cases, 38%) or low falls (197 cases, 28%). The overall crude incidence of TSCI was 1.26 cases per 100 000 population (95% CI, 1.17–1.36 per 100 000 population), and did not change over the study period (incidence rate ratio [IRR], 1.01; 95% CI, 0.99–1.04). However, the incidence of TSCI resulting from low falls increased by 9% per year (95% CI, 4–15%). The proportion of TSCI cases classified as incomplete tetraplegia increased from 41% in 2007 to 55% in 2016 (P < 0.001). Overall in-hospital mortality was 15% (104 deaths), and was highest among people aged 65 years or more (31%, 70 deaths). Conclusions: Given the devastating consequences of TSCI, improved primary prevention strategies are needed, particularly as the incidence of TSCI did not decline over the study period. The epidemiologic profile of TSCI has shifted, with an increasing number of TSCI events in older adults. This change has implications for prevention, acute and post-discharge care, and support.Ben Beck, Peter A Cameron, Sandra Braaf, Andrew Nunn, Mark C Fitzgerald, Rodney T Judson, Warwick J Teague, Alyse Lennox, James W Middleton, James E Harrison, Belinda J Gabb

GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility

Loss of maternal UBE3A causes Angelman syndrome (AS), a neurodevelopmental disorder associated with severe epilepsy. We previously implicated GABAergic deficits onto layer (L) 2/3 pyramidal neurons in the pathogenesis of neocortical hyperexcitability, and perhaps epilepsy, in AS model mice. Here we investigate consequences of selective Ube3a loss from either GABAergic or glutamatergic neurons, focusing on the development of hyperexcitability within L2/3 neocortex and in broader circuit and behavioral contexts. We find that GABAergic Ube3a loss causes AS-like increases in neocortical EEG delta power, enhances seizure susceptibility, and leads to presynaptic accumulation of clathrin-coated vesicles (CCVs)—all without decreasing GABAergic inhibition onto L2/3 pyramidal neurons. Conversely, glutamatergic Ube3a loss fails to yield EEG abnormalities, seizures, or associated CCV phenotypes, despite impairing tonic inhibition onto L2/3 pyramidal neurons. These results substantiate GABAergic Ube3a loss as the principal cause of circuit hyperexcitability in AS mice, lending insight into ictogenic mechanisms in AS

Influência do grão de sorgo como fonte de amido em ovinos alimentados com feno: parâmetros plasmáticos Influence of sorghum grain as a source of starch in sheep fed hay: plasma parameters

O objetivo deste trabalho experimental foi verificar a influência de diferentes níveis de grão de sorgo, como fonte de amido, nos parâmetros plasmáticos em ovinos alimentados com feno de capim-elefante (Pennisetum purpureum Schum). O sorgo foi utilizado em quatro níveis na dieta: 0, 15, 30 e 45%. Foram usados 12 ovinos machos castrados distribuídos em quatro tratamentos com três repetições. Foram coletadas seis amostras de sangue por animal logo antes da refeição da manhã (hora zero) e 1, 2, 3, 4, 6 e 8 horas após. O delineamento experimental foi o completamente casualizado. A 1ª hora após a refeição apresentou a maior concentração plasmática de uréia (53,3 mg/100 mL) e foi superior à 6ª e 8ª hora (49,5 e 49,3 mg/100 mL). A maior concentração de uréia no plasma coincidiu com a maior concentração de amônia no líquido ruminal. O tratamento com 30% de sorgo na dieta apresentou concentração plasmática de glicose de 81,0 mg/100 mL e foi superior ao tratamento testemunha (60,4 mg/100 mL). A concentração de insulina variou entre tratamentos para cada hora de coleta após a refeição, de acordo com os níveis de sorgo na dieta. O tratamento com 45% de sorgo apresentou a maior concentração do hormônio no plasma. Observou-se para todos os tratamentos um pico de produção do hormônio na 4ª hora após a refeição.<br>The objective of this experimental work was to evaluate the influence of different levels of sorghum grain, as a source of starch, on the plasma parameters of sheep fed elephant grass hay (Pennisetum purpureum Schum). Sorghum grain was included in the diet at four levels: 0, 15, 30 e 45%. Twelve castrated male sheep were assigned to four treatments with three replicates. Six samples of blood per animal were collected just before the morning feeding (zero hour) and after 1, 2, 3, 4, 6 and 8 hours. A completely randomized design was used. The first hour after feeding showed the highest plasma concentration of urea (53.3 mg/100 mL) and was higher than the six and eight-hour samples (49.5 and 49.3 mg/100 mL). The higher concentration of urea in the plasma coincided with the highest concentration of ammonia in the ruminal liquor. Treatment including 30% sorghum in the diet showed a glucose plasmatic concentration of 81,0 mg/100 mL and was superior to the control treatment (60.4 mg/100 mL). Insulin concentration varied among treatments for each hour of collection after feeding according to the levels of sorghum in the diet. The treatment that included 45% sorghum grain showed the highest concentration of this hormone in the plasma. It was observed a peak of the insulin production at the four-hour after feeding